Advertisement Genstar Capital takes over ERT - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Genstar Capital takes over ERT

Genstar Capital has completed the acquisition of the ERT in a take-private transaction valued at approximately $400m.

ERT is a technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations to achieve their drug development and healthcare objectives.

ERT CEO Jeffrey Litwin as a private company ERT will continue to serve its customers and enhance its suite of products.

"We have been able to grow our company into a global leader, and, with Genstar’s partnership, we will look for creative new ways to grow our business organically and identify new investment opportunities as part of our continued development," Litwin added.

Genstar Capital is a San Francisco-based private equity firm investing in high quality companies.

Genstar managing director Robert Weltman said, "ERT is already the global leader in its sector yet we believe the company can benefit from our expertise in the pharmaceuticals industry to create positive change that will drive operations at an increased pace."